title: Spinal-injured neuropathic bladder antisepsis (SINBA) trial.
abstract: OBJECTIVE
  To determine whether Methenamine Hippurate (MH) or cranberry tablets prevent urinary tract infections (UTI) in people with neuropathic bladder following spinal cord injury (SCI).
  
  
  METHODS
  Double-blind factorial-design randomized controlled trial (RCT) with 2 year recruitment period from November 2000 and 6 month follow-up.
  
  
  METHODS
  In total, 543 eligible predominantly community dwelling patients were invited to participate in the study, of whom 305 (56%) agreed.
  
  
  METHODS
  Eligible participants were people with SCI with neurogenic bladder and stable bladder management. All regimens were indistinguishable in appearance and taste. The dose of MH used was 1 g twice-daily. The dose of cranberry used was 800 mg twice-daily. The main outcome measure was the time to occurrence of a symptomatic UTI.
  
  
  RESULTS
  Multivariate analysis revealed that patients randomized to MH did not have a significantly longer UTI-free period compared to placebo (HR 0.96, 95% CI: 0.68-1.35, P=0.75). Patients randomized to cranberry likewise did not have significantly longer UTI-free period compared to placebo (HR 0.93, 95% CI: 0.67-1.31, P=0.70).
  
  
  CONCLUSIONS
  There is no benefit in the prevention of UTI from the addition of MH or cranberry tablets to the usual regimen of patients with neuropathic bladder following SCI.
authors.affiliation: Spinal Medicine Department, Prince of Wales Hospital, Sydney, New South Wales, Australia.
authors.forename: B B
authors.initials: BB
authors.lastname: Lee
authors.forename: M J
authors.initials: MJ
authors.lastname: Haran
authors.forename: L M
authors.initials: LM
authors.lastname: Hunt
authors.forename: J M
authors.initials: JM
authors.lastname: Simpson
authors.forename: O
authors.initials: O
authors.lastname: Marial
authors.forename: S B
authors.initials: SB
authors.lastname: Rutkowski
authors.forename: J W
authors.initials: JW
authors.lastname: Middleton
authors.forename: G
authors.initials: G
authors.lastname: Kotsiou
authors.forename: M
authors.initials: M
authors.lastname: Tudehope
authors.forename: I D
authors.initials: ID
authors.lastname: Cameron
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000892:Anti-Infective Agents, Urinary / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D006626:Hippurates / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008709:Methenamine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D008875:Middle Aged; D015999:Multivariate Analysis; D008517:Phytotherapy; D010936:Plant Extracts / Q000627:therapeutic use*; D013119:Spinal Cord Injuries / Q000150:complications*; D013607:Tablets; D017211:Treatment Failure; D001750:Urinary Bladder, Neurogenic / Q000188:drug therapy* / Q000209:etiology*; D014552:Urinary Tract Infections / Q000517:prevention & control*; D029799:Vaccinium macrocarpon / Q000737:chemistry*
chemical_list: D000892:Anti-Infective Agents, Urinary; D006626:Hippurates; D010936:Plant Extracts; D013607:Tablets; D008709:Methenamine; C011481:methenamine hippurate